High cholesterol is a significant risk factor for developing heart and circulatory diseases. In addition to behaviour changes, there are also a number of treatment options for high cholesterol. It is important to optimise lipid therapies, and several new options are available if statins are not tolerated or effective in reducing cholesterol to target. These include Ezetimibe, Bempedoic Acid, Inclisiran and PCSK9i and Icosapent ethyl.

Inclisiran was added to the NICE lipid management pathway in October 2021 as a secondary prevention option for patients treated with a maximum dose of statins and LDL >2.6 mmol/L.

In this webinar, we hope to cover education relevant to lipid optimisation which is an important aspect of CVD prevention. We will discuss the new lipid clinic referral form and newer treatment options such as bempedoic acid, PCSK9 inhibitors, inclisiran and icosapent ethyl which may be used to treat patients to achieve lipid targets. This session will have a particular focus on Inclisiran in primary care settings, identifying eligible patients and the pathway. We hope that you will find this session helpful and very relevant to your work.

Webinar content:

1) Launch of the new KSS lipid clinic referral form on all GP systems via Ardens

2) KSS Data for ICBs and PCNs (open prescribing data and CVDPrevent Audit)

3) New QOF indicators for cholesterol secondary prevention (CHOL001 and CHOL002)

4) Lipid Management – a practical guide and patient case examples

5) Implementing Inclisiran – clinical and operational overview

6) Education and training opportunities, resources and patient information

7) Q&A session

Speakers

Dr Richard Blakey: GPSI Cardiology, CVD Lead, Health Innovation KSS, CVD (hypertension) Clinical lead, NHS Sussex
Dr Kate Shipman: Consultant Chemical Pathologist, University Hospitals Sussex
Jen Bayly: Clinical Project Advisor for the CVD Prevention Programme at Health Innovation KSS

Webinar Objectives:

• Raised awareness of the new lipid clinic referral form and how to access it

• Overview of the new QOF indicators for cholesterol and the latest CVDPrevent Audit data.

• Understand where Inclisiran fits within the NICE Lipid Pathway

• Improve understanding of the operational considerations when providing Inclisiran

• Learn about the searches that exist to identify patients eligible for Inclisiran

• Hear examples of patients that would benefit from Inclisiran

• An opportunity to ask questions about the implementation of Inclisiran

This webinar is open to all colleagues across the South East with an interest or role in lipids management, please feel free to forward this invitation to colleagues.

We are running this webinar on two separate occasions. You only need to attend one session.

This webinar is open to all colleagues across the South East with an interest or role in lipids management.

For those who will not be able to join or have clinical commitments on these dates, the webinar will be recorded and will be made available with any resources that are also used during the session.

A Practical Guide to Lipids Management